STOCK TITAN

GSK Plc - GSK STOCK NEWS

Welcome to our dedicated news page for GSK Plc (Ticker: GSK), a resource for investors and traders seeking the latest updates and insights on GSK Plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect GSK Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of GSK Plc's position in the market.

Rhea-AI Summary
GSK and YMCA host events to raise awareness about RSV infection in older adults
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.34%
Tags
conferences
-
Rhea-AI Summary
GSK announces that AREXVY, a vaccine for Respiratory Syncytial Virus (RSV), is now available in major retail pharmacies in the US. The vaccine is recommended for individuals aged 60 and older to prevent RSV-lower respiratory tract disease. Medicare Part D patients will have no out-of-pocket expenses, and commercially insured patients may have coverage at no cost when administered in-network.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.78%
Tags
-
Rhea-AI Summary
LimmaTech Biologics has signed an in-license agreement with GlaxoSmithKline Biologicals to develop and commercialize a quadrivalent bioconjugate vaccine candidate for shigellosis. The vaccine is being tested in a Phase I/II study, with results expected in 2023. Shigellosis causes 600,000 deaths annually and there is an urgent need for a vaccine. LimmaTech Bio is an independently owned Swiss biotech company that spun out from GlycoVaxyn after its acquisition by GSK in 2015.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.45%
Tags
none
-
Rhea-AI Summary
GSK has started shipping doses of its quadrivalent influenza vaccines to US healthcare providers and pharmacies for the 2023-24 flu season. The company expects to distribute over 40 million doses of its influenza vaccine to the US market. The vaccines are available in a 0.5mL, single-dose, pre-filled syringe and are recommended for patients six months and older.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.53%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.51%
Tags
none
GSK Plc

NYSE:GSK

GSK Rankings

GSK Stock Data

83.44B
3.91B
0.06%
14.42%
0.24%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United Kingdom
Brentford

About GSK

GSK plc, formerly GlaxoSmithKline plc, is a British multinational pharmaceutical and biotechnology company with global headquarters in London, England.